Literature DB >> 2424931

Alterations in the half-life and clearance of IgG during therapy with intravenous gamma-globulin in 16 patients with severe primary humoral immunodeficiency.

R I Schiff, C Rudd.   

Abstract

Published studies of the metabolism of human IgG using trace amounts of radiolabeled IgG demonstrated that the elimination of native IgG followed first-order kinetics but that the half-life of IgG was shortest in patients with the highest serum concentrations of IgG. To evaluate the effect of increasing the serum concentration of IgG on the metabolism of IgG, we determined the half-life and clearance of IgG and tetanus antibody in 16 patients with severe primary humoral immunodeficiency diseases while they received several doses of intravenous gamma-globulin (IVIG). Each patient received 100 mg/kg of IVIG each month and the half-life and clearance of IVIG were determined by following the decline in the serum IgG concentration. The dose of IVIG was adjusted to give a minimum IgG level of 200 mg/dl and the half-life was reevaluated. The dose was again adjusted to give minimum concentrations of 450 mg/dl and two additional studies were performed. Mean doses of IVIG infused increased from 100 to 346 mg/kg. The mean trough serum IgG concentration was 191 mg/dl on the standard dose and increased to 427 mg/dl at the highest dose. The serum half-lives of IgG were highly variable, ranging from 22 to 96 days. The mean decreased from 43 days in the first to 33 days in the third and fourth studies, and the clearances of IgG increased from 1.8339 to 2.4302 mg/kg/day, but the differences were not statistically significant. Patients with the highest serum IgG concentrations tended to have the longest half-lives, suggesting that intrinsic IgG production might falsely prolong the calculated half-life of IgG.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2424931     DOI: 10.1007/bf00918706

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  16 in total

1.  FACTORS CONTROLLING SERUM GAMMA-GLOBULIN CONCENTRATION.

Authors:  J L FAHEY; A G ROBINSON
Journal:  J Exp Med       Date:  1963-11-01       Impact factor: 14.307

2.  [Antibody titer after intravenous gamma-globulin therapy].

Authors:  B Kornhuber
Journal:  Klin Wochenschr       Date:  1973-02-01

3.  Serum immunoglobulins. I. Levels in normal children and in uncomplicated childhood allergy.

Authors:  R H Buckley; S C Dees; W M O'Fallon
Journal:  Pediatrics       Date:  1968-03       Impact factor: 7.124

Review 4.  Metabolism of immunoglobulins.

Authors:  T A Waldmann; W Strober
Journal:  Prog Allergy       Date:  1969

5.  Survival studies on a commercial preparation of intravenous human gammaglobulin labelled with 131-I.

Authors:  J V Wells; R Penny
Journal:  Australas Ann Med       Date:  1969-08

6.  Undegraded human immunoglobulin for intravenous use.

Authors:  W Stephan
Journal:  Vox Sang       Date:  1975       Impact factor: 2.144

7.  Use of intravenous gamma-globulin in antibody immunodeficiency: results of a multicenter controlled trial.

Authors:  A J Ammann; R F Ashman; R H Buckley; W R Hardie; H J Krantmann; J Nelson; H Ochs; E R Stiehm; T Tiller; D W Wara; R Wedgwood
Journal:  Clin Immunol Immunopathol       Date:  1982-01

8.  Individual patient variations in the kinetics of intravenous immune globulin administration.

Authors:  B Pirofsky; S M Campbell; A Montanaro
Journal:  J Clin Immunol       Date:  1982-04       Impact factor: 8.317

9.  Use of a new chemically modified intravenous IgG preparation in severe primary humoral immunodeficiency: clinical efficacy and attempts to individualize dosage.

Authors:  R I Schiff; C Rudd; R Johnson; R H Buckley
Journal:  Clin Immunol Immunopathol       Date:  1984-04

10.  EVIDENCE FOR SPECIES' DIFFERENCES IN THE EFFECT OF SERUM GAMMA-GLOBULIN CONCENTRATION ON GAMMA-GLOBULIN CATABOLISM.

Authors:  S SELL
Journal:  J Exp Med       Date:  1964-11-01       Impact factor: 14.307

View more
  8 in total

Review 1.  New and old aspects of immunoglobulin application. The use of intravenous IgG as prophylaxis and for treatment of infections.

Authors:  L Hammarström; C I Smith
Journal:  Infection       Date:  1990 Sep-Oct       Impact factor: 3.553

2.  Multicenter crossover comparison of the safety and efficacy of Intraglobin-F with Gamimune-N, Sandoglobulin, and Gammagard in patients with primary immunodeficiency diseases.

Authors:  R I Schiff; L W Williams; R P Nelson; R H Buckley; W Burks; R A Good
Journal:  J Clin Immunol       Date:  1997-01       Impact factor: 8.317

3.  Half-life of the maternal IgG1 allotype in infants.

Authors:  H Sarvas; I Seppälä; S Kurikka; R Siegberg; O Mäkelä
Journal:  J Clin Immunol       Date:  1993-03       Impact factor: 8.317

Review 4.  Immunoglobulin replacement therapy in children.

Authors:  Maria Garcia-Lloret; Sean McGhee; Talal A Chatila
Journal:  Immunol Allergy Clin North Am       Date:  2008-11       Impact factor: 3.479

5.  Treatment of Pediatric Acute-Onset Neuropsychiatric Disorder in a Large Survey Population.

Authors:  Denise Calaprice; Janice Tona; Tanya K Murphy
Journal:  J Child Adolesc Psychopharmacol       Date:  2017-08-23       Impact factor: 2.576

6.  Misleading Positive Serology for Cat Scratch Disease following Administration of Intravenous Immunoglobulin.

Authors:  Michal Yakubovsky; Yoav Golan; Alex Guri; Itzhak Levy; Daniel Glikman; Moshe Ephros; Michael Giladi
Journal:  Pathogens       Date:  2022-01-27

7.  Vaccination with rabies to study the humoral and cellular immune response to a T-cell dependent neoantigen in man.

Authors:  D M C Brinkman; C M Jol-van der Zijde; M M ten Dam; J M Vossen; A D M E Osterhaus; F P Kroon; M J D van Tol
Journal:  J Clin Immunol       Date:  2003-11       Impact factor: 8.542

Review 8.  In Translation: FcRn across the Therapeutic Spectrum.

Authors:  Timothy Qi; Yanguang Cao
Journal:  Int J Mol Sci       Date:  2021-03-17       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.